Clinical Trials — World Parkinson Congress Blog

Posts tagged Clinical Trials

Could Subgrouping Parkinson’s Disease Using Cellular Phenotyping Enable Success at Clinical Trials?

Could Subgrouping Parkinson’s Disease Using Cellular Phenotyping Enable Success at Clinical Trials?

by Toby Burgess PhD Student

Basic ScienceToby Burgess PhD StudentMarch 13, 2024Parkinson, Clinical Trials, Brain, NineComment

Proactive Integrated Management and Empowerment in Parkinson’s

Proactive Integrated Management and Empowerment in Parkinson’s

by Dr Katie Lloyd MBChB MRCP (UK) BSc

Clinical ScienceDr Katie Lloyd MBChB MRCP BScNovember 20, 2023parkinsons, Health Care, Care Models, Clinical Trials, Process evaluation, Eight Comments

Clinical Alpha-Synuclein Biomarker Urgently Needed!

Clinical Alpha-Synuclein Biomarker Urgently Needed!

Thomas G Beach, MD, PhD

Basic ScienceThomas G Beach, MD, PhDJuly 6, 2021Parkinson's, Diagnosis, Alpha-Synuclein, Target engagement, Clinical Trials, Monoclonal Antibody, Biopsy, six Comment

Why Participate in Clinical Trials?

Why Participate in Clinical Trials?

by Soania Mathur, MD

Clinical ScienceSoania Mathur, MDMarch 22, 2021Parkinson's, Clinical Trials, Medical Research, Patient Recruitment, sixComment

Disease Modifying Trials

Disease Modifying Trials

by Simon Lewis, MB, BCh, BSc, MD

Clinical ScienceSimon LewisDecember 11, 2019Parkinson's, Clinical Trials, Disease Progression, study, four Comment

Can wearable technology improve clinic visits or clinical trials?

Can wearable technology improve clinic visits or clinical trials?

by Corinne Jones, PhD, CCC-SLP

Clinical ScienceCorinne Jones, PhD, CCC-SLPOctober 7, 2019Clinical Trials, technology, wearable technology, four Comment

Is there any future in the use of growth factors to repair the brain in Parkinson’s disease?

Is there any future in the use of growth factors to repair the brain in Parkinson’s disease?

Roger A Barker, MRCP PhD FMedSci

Clinical ScienceRoger Barker PhD MRCPAugust 20, 2019Parkinson's Disease, GDNF, Clinical Trials, fourComment

The FDA and Oversight of Stem Cells: Implications for Parkinson’s Disease

The FDA and Oversight of Stem Cells: Implications for Parkinson’s Disease

by Jeffrey H. Kordower, PhD and Patrik Brundin MD, PhD

Clinical ScienceJeffrey H. Kordower PhDSeptember 25, 2017Stem Cells, Clinical Trials, FDA, September 2017, one, FirstComment